The US Food and Drug Administration (FDA) has approved an abbreviated new drug application for a generic version of Pfizer’s Procardia XL tablets as a treatment for angina and hypertension.
Nifedipine extended-release tablets USP (30mg, 60mg and 90mg) have been developed by Mylan Pharmaceuticals, a subsidiary of US-based Mylan.
Pharmaceutical intelligence agency IMS Health said that Nifedipine tablets had US sales of approximately $234m for the year ending 31 March 2010.
Mylan is a pharmaceutical company that focuses on respiratory, allergy and psychiatric therapies.
Share this article
